Dyspnea Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

Dyspnea Treatment Market is expected to grow at a registered CAGR of 4.5% during the forecast period.

According to the study titled "Dyspnea: The vanished warning symptom of COVID-19 pneumonia" published in November 2020, dyspnea is slightly more common in patients who develop acute SARS-CoV-2 infection and have the worst clinical outcomes. In the general population, in people with chronic obstructive pulmonary disease, dyspnea has been strongly linked to a poor prognosis. Moreover, as per the same source, less than 50% of SARS-COV-2 infected patients had been reported to experience dyspnea, a subjective feeling of breathing discomfort. As a result, it was anticipated that demand for dyspnea treatments would increase; however, because of a weak supply chain, the market suffers during a pandemic

The increase in the prevalence of COPD and asthma, which are the main causes of dyspnea and its causative symptoms, is what is driving the global market for dyspnea treatments. The main causes of dyspnea are a high prevalence of cardiopulmonary diseases, a rise in obesity among people, and alterations in lifestyle. According to the study titled "Prevalence and severity of different dimensions of breathlessness among elderly males in the population" published in the European Respiratory Journal in February 2022, breathlessness has been a common symptom of cardiorespiratory disease, as well as a prevalent symptom in the general population. Shortness of breath affects 10-25% of adults in their middle years and older during regular activity. Therefore, increasing dyspnea prevalence is anticipated to result in increased demand for its management and treatment, which will propel market expansion. Additionally, COPD and asthma are the main contributors to dyspnea, and the rising prevalence of these conditions will fuel market expansion over the forecast period. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), that affects both children and adults. Globally, around 262 million people had asthma in 2020, which is expected to boost the demand of dyspnea treatment among people suffering from Asthma.

Furthermore, the global market for dyspnea treatments is expanding as a result of rising air pollution levels and toxicity exposure that causes breathlessness in the populace. According to the United States Environmental Protection Agency in June 2022, health could be negatively impacted by ozone in the air, especially on hot, sunny days when ozone levels could rise dangerously high. People with asthma, children, elderly people, and those who engage in outdoor activities were at risk from breathing ozone-containing air. Thus, increasing exposure to toxic substances and air pollution may significantly increase the likelihood of developing dyspnea, fueling the market growth over the projected period.

Thus, all aforementioned factors are expected to boost the market growth over the forecast period, however, the high cost associated with the treatment may restrain the market growth.

Key Market Trends

Supplemental Oxygen Therapy is Expected to Witness Healthy Growth Over the Forecast Period

Supplemental oxygen is the use of oxygen as a medicinal treatment. Acute indications for therapy include hypoxemia, carbon monoxide poisoning, and cluster headache. It may also be administered prophylactically to maintain blood oxygen levels during anesthesia induction.

Patients with other chronic lung diseases such as dyspnea are frequently prescribed oxygen therapy because it improves the quality of life and increases survival in hypoxemic patients with chronic obstructive pulmonary disease (COPD). According to the study titled "Long-term supplemental oxygen therapy" by Rick Carter published in March 2022, in the United States, 1.5 million patients received oxygen therapy each year. Thus, it is anticipated that the market will grow during the forecast period due to the rising trend of using oxygen therapy for respiratory conditions, including dyspnea.

According to the study titled "Administration of Supplemental Oxygen" published in the New England Journal of Medicine in July 2021, the study reported that supplemental oxygen is the most effective component in the treatment of dyspnea. Supplemental oxygen therapy improves sleep, mood, mental clarity, endurance, and the ability of people with some types of lung disease to perform regular, everyday tasks. In patients with severe lung diseases, additional oxygen therapy helps prevent heart failure. As a result of the additional advantages of oxygen therapy, the market is anticipated to expand throughout the forecast period.

Growing funding for oxygen therapy support is anticipated to accelerate the segment's growth. For instance, in June 2022, the United States Agency for International Development (USAID) has advanced plans for a previously announced USD 50 million investment to increase access to medical oxygen worldwide, beginning with commitments to build and enhance health care infrastructure to support bulk liquid oxygen in 50 facilities around the world. According to estimates from USAID, the investment will support the provision of medical oxygen at more than 20,000 beds, allowing thousands of patients to receive oxygen therapy every year. Moreover, the Global Fund invested around USD 600 million to help more than 80 lower-middle-income countries increase patient access to medical oxygen, and the United States is the fund's single-largest donor. Such government initiatives lower the cost for the patient population, which ultimately accelerates the segment's growth.

Thus, owing to the above factors the segment is expected to show a healthy growth rate over the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America dominated the global dyspnea treatment market due to the presence of major market players, an increase in product approvals, a developed health care system, and a high prevalence of obesity and cardiopulmonary diseases.

According to the study titled "Respiratory Symptoms among US Adults: A Cross-Sectional Health Survey Study" published in Pulmonary Therapy in July 2022, the most common respiratory symptom, followed by a productive cough and shortness of breath, affects 17% of adult Americans every year. Morbid obesity was the most common comorbidity in subjects reporting this symptom, even though asthma, chronic obstructive pulmonary disease (COPD), and coronary heart disease were common causes of dyspnea on exertion. Moreover, the growing prevalence of these diseases is expected to boost the market growth. As per the Office of Disease Prevention and Health Promotion (ODPHP) 2020, more than 25 million people in the United States had asthma and approximately 14.8 million adults have been diagnosed with COPD.

Additionally, it is anticipated that a growing air population and harmful toxins will support market expansion. The United States Environmental Protection Agency in June 2022, in the United States, approximately 67 million tons of pollution were released into the atmosphere in 2021. These emissions primarily cause ozone and particle formation, acid deposition, and reduced visibility. this might result in several respiratory conditions, like breathing difficulties (dyspnea).

A growing number of clinical trials are anticipated to introduce better treatment options for diseases, which is anticipated to spur market expansion. According to the Clinitrials.gov updates in February 2022, the study titled "Dexamethasone in Controlling Dyspnea in Patients with Cancer" by the National Cancer Institute (NCI), the study has accessed the effectiveness of dexamethasone in managing dyspnea in cancer patients. In cancer patients, dexamethasone may enhance lung function, reduce dyspnea (shortness of breath), and enhance the quality of life. So, it may be anticipated that this will launch soon and aid in the expansion of the market under consideration.

Thus, owing to all above-mentioned factors the market is expected to witness high growth

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. With the rising technological advancements and product innovations, mid-size and small-scale companies are increasing their market presence by introducing new devices into the market at competitive prices. Some of the market players are Mayne Pharma Group Limited, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline, Hikma Pharmaceuticals plc, and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support